Results At-A-Glance

The Pediatric Trials Network works to make medication safer and more effective for all children. As part of that work, we share what we learn with research participants and the general public through Results-at-a-Glance summaries. We appreciate every family who participates in research and makes this work possible.

Lorazepam Results-at-a-Glance
Completed: December 1, 2024
This summary describes a study performed by the Pediatric Trials Network (PTN). The study was needed to find out how children with status epilepticus process lorazepam.
Oxcarbazepine Results-at-a-Glance
Completed: November 1, 2024
This summary describes a study by the Pediatric Trials Network (PTN). The study learned how a child's obesity status might affect the way they process oxcarbazepine.
Diazepam Results-at-a-Glance
Completed: October 1, 2024
This summary describes an analysis by the Pediatric Trials Network (PTN) of a study that looked at how children process diazepam. It learned how much diazepam to give to children for treatment of seizures.

Rifampin Results-at-a-Glance
Completed: September 1, 2024
This summary describes a summary by the Pediatric Trials Network (PTN). It learned how infants process rifampin.

Levetiracetam Results at-a-Glance
Completed: August 1, 2024
This summary describes two studies by the Pediatric Trials Network (PTN). These studies learned how children who are heavier than average weight process levetiracetam and how much they should receive for treating seizures.
Sildenafil Results-at-a-Glance
Completed: July 1, 2024
This summary describes a study by the Pediatric Trials Network (PTN). The study learned how infants process sildenafil.
Oxycodone Results-at-a-Glance
Completed: June 1, 2024
This summary describes a study by the Pediatric Trials Network (PTN) called “Commonly Used Drugs During Lactation and Infant Exposure (CUDDLE)." The study tested medicines, including oxycodone, to learn how they transfer from mother to baby through breastmilk.
Fluconazole Results-at-a-Glance
Completed: April 1, 2024
This summary describes four studies supported by the Pediatric Trials Network (PTN). They evaluated the safety and effectiveness of fluconazole for preventing and treating yeast infections in infants born prematurely and full-term.
Ticarcillin-clavulanate Results-at-a-Glance
Completed: February 1, 2024
This summary describes a study by the Pediatric Trials Network (PTN). It learned how infants born prematurely process ticarcillin-clavulanate.
Clindamycin Results-at-a-Glance
Completed: October 1, 2023
This summary describes two studies by the Pediatric Trials Network (PTN). These studies aimed to learn the safest, most effective dosage of clindamycin in children ranging in age from premature infants to adolescents.

Metronidazole Results-at-a-Glance
Completed: July 1, 2023
This summary describes an analysis by the Pediatric Trials Network (PTN). The study learned about the safest and most effective dosage of metronidazole for treated complicated intra-abdominal infections in infants.

PPE Results-at-a-Glance
Completed: March 1, 2023
This summary describes three studies by the Pediatric Trials Network (PTN). The studies learned how wearing personal protective equipment (PPE) impacts health care providers' ability to perform emergency care for children.
babyTAPE Results-at-a-Glance
Completed: November 1, 2022
This summary describes the BabyTAPE studies performed by the Pediatric Trials Network (PTN). The studies developed a formula and device to accurately estimate the weight of infants.

Ampicillin Results-at-a-Glance
Completed: June 1, 2022
This summary describes a study by the Pediatric Trials Network (PTN) called the "Ampicillin in Infants Study." The goal of the study was to find out how newborns process ampicillin and determine the safest and most effective dose to treat infections.

Caffeine Citrate Results-at-a-Glance
Completed: January 1, 2022
This summary describes a study by the Pediatric Trials Network (PTN). The study was needed to identify the association of caffeine citrate use and safety in infants less than 29 weeks gestational age and to bridge the gap in caffeine citrate’s label recommendations and current clinical practice.

POP01 Results-at-a-Glance
Completed: August 1, 2021
This summary describes a study by the Pediatric Trials Network (PTN). The study aimed to learn and provide dosing guidelines and recommendations for medicines that are understudied in children.

Meropenem Results-at-a-Glance
Completed: July 1, 2020
This summary describes a study by the Pediatric Trials Network (PTN). The study learned how infants younger than three months old process meropenem.

Lisinopril Results-at-a-Glance
Completed: June 1, 2020
This summary describes a study by the Pediatric Trials Network (PTN). The study learned the ideal dosage of lisinopril for treating high blood pressure in children who received a kidney transplant.

Acyclovir Results at-a-Glance
Completed: June 1, 2020
This summary describes a study by the Pediatric Trials Network (PTN) called The “Open-Label Study to Describe the Pharmacokinetics of Acyclovir in Premature Infants.” The study was conducted in order to learn more about the appropriate level of acyclovir dosing for infants.